IP Protection for Biologics in the TPP: Trading Away Future Treatments and Cures
2 12 2015IPWatchdog
October 26, 2015
Dr. Kristina Lybecker
Globally there are approximately 7,000 medicines in development to treat and cure a wide variety of diseases. Of these, more than 5,000 are in development in the United States. It’s difficult to argue that the strength and success of the U.S. biopharmaceutical industry is uncorrelated with the IP protection available here. It is, therefore, disappointing that the recently negotiated Trans-Pacific Partnership (TPP) Trade Agreement fails to deliver sufficient IP protection for biologics. Much of the continuing controversy plaguing the TPP Agreement surrounds data exclusivity protection for biologic medicines and the future of the agreement may hinge on precisely this issue.
The content in this post was found at http://www.ipwatchdog.com/2015/10/26/ip-protection-for-biologics-in-the-tpp-trading-away-future-treatments-and-cures/id=62692/ and was not authored by the moderators of freeforafee.com. Clicking the title link will take you to the source of the post.
